Stacey Nabors
About Stacey Nabors
Stacey Nabors serves as the Associate Director of CMC Regulatory Affairs at Nektar Therapeutics, where she has worked since 2016. She holds a Bachelor of Science in Biology and Chemistry from The University of West Alabama and a Master of Science from The University of Georgia.
Work at Nektar Therapeutics
Stacey Nabors has held multiple positions at Nektar Therapeutics since joining the company in 2002. She began her career there as a Scientist, working for seven years until 2009. Following this role, she advanced to Senior Regulatory Affairs Specialist, where she contributed for four years until 2013. Nabors then took on the role of Manager, Regulatory Affairs, which she has held for eleven years. In 2016, she was promoted to Associate Director, CMC Regulatory Affairs, a position she continues to occupy. All her roles at Nektar Therapeutics have been based in South San Francisco, California.
Education and Expertise
Stacey Nabors earned her Bachelor of Science degree in Biology and Chemistry from The University of West Alabama, where she studied from 1993 to 1998. She later pursued a Master of Science degree at The University of Georgia, completing her studies between 2011 and 2013. Her educational background provides a strong foundation for her work in regulatory affairs and scientific research.
Background in Pharmaceuticals
Before joining Nektar Therapeutics, Stacey Nabors worked at Vintage Pharmaceuticals as a QC Chemist from 1998 to 2002. This role contributed to her understanding of quality control processes within the pharmaceutical industry, which she has applied throughout her career in regulatory affairs.
Career Progression
Stacey Nabors has demonstrated significant career progression within Nektar Therapeutics. Starting as a Scientist, she transitioned through various roles, including Senior Regulatory Affairs Specialist and Manager of Regulatory Affairs, before reaching her current position as Associate Director. Her extensive experience in regulatory affairs reflects her commitment to the pharmaceutical sector.